Shattuck Labs, Inc. (STTK) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 100.36M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 100.36M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 100.36M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 100.36M | (m) | (m) |
| 2026-03-31 | 76.68M | (m) | (m) |
| 2025-12-31 | 71.56M | (m) | (m) |
| 2025-09-30 | 63.28M | (m) | (m) |
| 2025-06-30 | 47.90M | (m) | (m) |
| 2025-03-31 | 47.90M | (m) | (m) |
| 2024-12-31 | 47.90M | (m) | (m) |
| 2024-09-30 | 47.74M | (m) | (m) |
| 2024-06-30 | 47.73M | (m) | (m) |
| 2024-03-31 | 47.55M | (m) | (m) |
| 2023-12-31 | 47.47M | (m) | (m) |
| 2023-09-30 | 42.49M | (m) | (m) |
| 2023-06-30 | 42.47M | (m) | (m) |
| 2023-03-31 | 42.47M | (m) | (m) |
| 2022-12-31 | 42.45M | (m) | (m) |
| 2022-09-30 | 42.39M | (m) | (m) |
| 2022-06-30 | 42.38M | (m) | (m) |
| 2022-03-31 | 42.38M | (m) | (m) |
| 2021-12-31 | 42.36M | (m) | (m) |
| 2021-09-30 | 42.25M | (m) | (m) |
| 2021-06-30 | 42.12M | (m) | (m) |
| 2021-03-31 | 41.90M | (m) | (m) |
| 2020-12-31 | 41.78M | (m) | (m) |
| 2020-09-30 | 41.74M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |